UCB Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Jean-Christophe Tellier
Algemeen directeur
€12.4m
Totale compensatie
| Percentage CEO-salaris | 11.26% |
| Dienstverband CEO | 11.4yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 5.9yrs |
| Gemiddelde ambtstermijn bestuur | 8.7yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Jun 05
UCB: Epilepsy Reliance Will Eventually Clash With Lupus And Pipeline Uncertainty
UCB's analyst price target has been raised from €209.22 to €221.55, with analysts pointing to updated assumptions around slightly higher projected revenue growth, a modestly higher discount rate, broadly steady profit margins, and a small adjustment to future P/E expectations. Analyst Commentary Recent Street research on UCB highlights that not all analysts are leaning in the same direction, even with a higher price target.
Narratiefupdate • May 15
UCB: Epilepsy Blockbusters And Neuroscience Pipeline Will Drive Future Upside Potential
Analysts have nudged their average price target for UCB higher, with fair value moving from €284.65 to about €288.21 as they factor in updated assumptions on discount rate, revenue growth, profit margins, and future P/E, supported by recent target hikes and fresh Outperform ratings on the stock. Analyst Commentary Recent research points to a split but constructive view on UCB, with several firms adjusting ratings and targets as they reassess the stock's risk and reward profile.
Narratiefupdate • Apr 30
UCB: Epilepsy Portfolio Execution To Drive Future Earnings Power Upside
The analyst fair value estimate for UCB has shifted from €310 to €340, reflecting updated assumptions on revenue growth, higher projected profit margins, a slightly adjusted discount rate, a revised future P/E, and recent Street research in which analysts highlight UCB's epilepsy portfolio and reset price targets in the €300 to €340 range. Analyst Commentary Recent Street research on UCB has been mixed, with some caution on near-term risk and reward but also clear pockets of optimism tied to its neuroscience and epilepsy franchises.Narratiefupdate • Apr 16
UCB: Epilepsy And Neuroscience Execution Will Shape Balanced Risk Reward Profile
Analysts have adjusted the UCB price target toward €285, reflecting a blend of more cautious views that see risk and reward as balanced around €260 and more optimistic calls pointing toward €304 to €340, supported by expectations for its epilepsy portfolio and broader neuroscience exposure. Analyst Commentary Bullish Takeaways Bullish analysts see upside toward €304 to €340, suggesting that current pricing does not fully reflect expectations around the epilepsy portfolio and broader neuroscience pipeline.Narratiefupdate • Apr 01
UCB: Epilepsy Franchise And Dermatology Data Will Shape Future Risk Reward Balance
Narrative Update on UCB The analyst price target for UCB has been adjusted slightly lower to about €285. This reflects a blend of more cautious views that see a balanced risk and reward at current levels, and more optimistic targets that highlight UCB's epilepsy portfolio and recent upward revisions from several banks.Narratiefupdate • Mar 18
UCB: Epilepsy And Psoriatic Arthritis Execution Will Shape Future Risk Reward Balance
The updated analyst price target for UCB moves to €284.85 from €275.74. This reflects a mix of more conservative revenue growth assumptions, higher expected profit margins, and a lower future P/E multiple, in line with recent research that balances enthusiasm around epilepsy assets with a more measured view on risk and reward.Narratiefupdate • Mar 04
UCB: Epilepsy Franchise Expectations Will Eventually Strain Current Share Price
We are lifting our fair value estimate for UCB from €173.07 to €209.22, reflecting higher assumed revenue growth and profit margins as analysts highlight a stronger outlook for the epilepsy franchise and raise price targets into the €300+ range. Analyst Commentary Recent Street research on UCB has centered on the epilepsy franchise and the broader neuroscience portfolio, with several firms updating their views and price targets.Narratiefupdate • Feb 18
UCB: Epilepsy Pipeline Progress And Execution Will Shape Future Upside Balance
Our Analyst Price Target for UCB has moved higher from €261.42 to €275.74, reflecting analysts' updated assumptions on revenue growth, profitability and P/E in light of recent Street target lifts to around €304 to €310. Analyst Commentary Recent Street research on UCB has centered on higher price targets, with bullish analysts adjusting their views to reflect updated assumptions on revenue, profitability and P/E.Narratiefupdate • Feb 04
UCB: Future Earnings Power To Reflect Rare Disease And Epilepsy Execution
Analysts have raised their price target on UCB to €310 from €270, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple as the main drivers of the change. Analyst Commentary Recent commentary from bullish analysts has centered on higher valuation support for UCB, with the new €310 price target used as a reference point for what they see as stronger execution and earnings potential than previously modeled.Narratiefupdate • Jan 21
UCB: Late-Stage Pipeline And Margin Execution Will Shape Balanced Upside Potential
Analysts raised their price target on UCB to €310 from €270, citing updated expectations for slightly stronger revenue growth, improved profit margins, and a modestly lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher €310 target as a sign that they see current valuation as not fully reflecting updated revenue and margin expectations.Narratiefupdate • Jan 07
UCB: Raising Future Fair Value On Strengthening Rare Disease And Epilepsy Franchise
Analysts have raised their fair value estimate for UCB from €255 to €310, citing recent price target increases from the Street and updated assumptions on revenue growth, profit margins and future P/E levels. Analyst Commentary Bullish analysts have recently adjusted their views on UCB, with fresh price targets that now cluster around €290 to €310.Narratiefupdate • Dec 18
UCB: Expanding Late-Stage Pipeline And New Launches Will Drive Future Upside
UCB's analyst price target has been raised from EUR 258.33 to EUR 264.67 as analysts factor in slightly stronger revenue growth expectations, despite a modestly lower projected profit margin and only a small uptick in future valuation multiples. Analyst Commentary Recent price target increases signal that bullish analysts see a more attractive risk reward profile for UCB, driven by improving growth visibility and confidence in execution.Narratiefupdate • Dec 04
UCB: Pipeline Execution And New Launches Will Support Balanced Future Upside Potential
UCB's fair value estimate has been nudged higher to approximately EUR 258 from EUR 257, reflecting analysts' upward revisions to price targets, with recent moves to EUR 240, EUR 285 and EUR 290. These changes highlight confidence in the company's earnings trajectory despite slightly softer margin and growth assumptions.Narratiefupdate • Nov 20
UCB: Recent Pipeline Advances And Margin Strength Will Drive Share Price Higher
Analysts have slightly raised their fair value estimate for UCB to €256.67. They cite recent upward revisions to price targets, supported by continued expectations for stable profit margins and healthy revenue growth.Analyseartikel • Nov 11
UCB (EBR:UCB) Could Easily Take On More Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narratiefupdate • Nov 06
UCB: Strong Profit Margins And Momentum Will Drive Shares Higher
UCB's fair value estimate has increased by approximately EUR 4.50, as analysts highlight robust performance and upward revisions to price targets. This follows renewed confidence in the company’s profit margin outlook.Narratiefupdate • Oct 22
Analysts Raise UCB Price Targets Amid Positive Sector Outlook and Improved Growth Forecasts
UCB's analyst price target has been raised from €240.28 to €251.11, as analysts cite upward revisions to revenue growth forecasts along with an improved sector outlook. Analyst Commentary Recent analyst actions reflect a strongly positive sentiment toward UCB's outlook, as multiple firms have revised their price targets upward and maintained favorable ratings.Analyseartikel • Oct 14
Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher
UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...Narratiefupdate • Oct 08
Aging Populations And Emerging Markets Will Unlock Opportunity
UCB's analyst price target has been increased from €229.06 to €240.28. This change reflects improved revenue growth expectations and profit margins highlighted by recent analyst updates.Narratiefupdate • Sep 24
Aging Populations And Emerging Markets Will Unlock Opportunity
The slight increase in UCB’s consensus price target to €229.06 reflects improved revenue growth forecasts, while profit margin expectations remain stable. What's in the News Three-year data from BE HEARD trials show sustained efficacy and quality of life improvements with BIMZELX® in moderate-to-severe hidradenitis suppurativa, with better outcomes linked to earlier treatment.Narratiefupdate • Aug 27
Aging Populations And Emerging Markets Will Unlock Opportunity
Analysts have raised their price target for UCB to €223.17, citing robust fundamentals, resilient earnings growth, and improved confidence in management despite recent share price weakness. Analyst Commentary Recent share price pullback seen as disconnected from underlying business strength.Analyseartikel • Jul 17
UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing
When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 14x, you may consider UCB...
Nieuw narratief • Mar 02
BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology
UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Dec 31 2025 | €12m | €1m | €2b |
| Sep 30 2025 | n/a | n/a | €1b |
| Jun 30 2025 | n/a | n/a | €1b |
| Mar 31 2025 | n/a | n/a | €1b |
| Dec 31 2024 | €7m | €1m | €1b |
| Sep 30 2024 | n/a | n/a | €653m |
| Jun 30 2024 | n/a | n/a | €240m |
| Mar 31 2024 | n/a | n/a | €292m |
| Dec 31 2023 | €7m | €1m | €343m |
| Jun 30 2023 | n/a | n/a | €332m |
| Mar 31 2023 | n/a | n/a | €376m |
| Dec 31 2022 | €6m | €1m | €420m |
| Jun 30 2022 | n/a | n/a | €887m |
| Mar 31 2022 | n/a | n/a | €971m |
| Dec 31 2021 | €6m | €1m | €1b |
| Sep 30 2021 | n/a | n/a | €996m |
| Jun 30 2021 | n/a | n/a | €936m |
| Mar 31 2021 | n/a | n/a | €834m |
| Dec 31 2020 | €7m | €1m | €732m |
| Jun 30 2020 | n/a | n/a | €743m |
| Mar 31 2020 | n/a | n/a | €767m |
| Dec 31 2019 | €87k | n/a | €790m |
Compensatie versus markt: De totale vergoeding ($USD 14.35M ) Jean-Christophe } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Belgian markt ($USD 2.84M ).
Compensatie versus inkomsten: De vergoeding van Jean-Christophe is het afgelopen jaar met meer dan 20% gestegen.
CEO
Jean-Christophe Tellier (67 yo)
11.4yrs
Tenure
€12,434,367
Compensatie
Dr. Jean-Christophe Tellier is Supervisory Board Member of LES LABORATOIRES SERVIER, SAS from March 2022. Dr. Tellier is Chief Executive Officer of UCB Ventures S.A. Dr. Jean-Christophe Tellier is CEO & Ex...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 11.4yrs | €12.43m | geen gegevens | |
| Executive VP & CFO | 5.9yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief Scientific Officer | 2.1yrs | geen gegevens | geen gegevens | |
| Executive VP & General Counsel | 3.2yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief Human Resources Officer | 6.3yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Patient Evidence | 11.3yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Patient Supply | 2.4yrs | geen gegevens | geen gegevens | |
| Executive VP of Patient Impact & Chief Commercial Officer | 2.2yrs | geen gegevens | geen gegevens | |
| Chief Accounting Officer & Head of Group Finance | 13.3yrs | geen gegevens | geen gegevens | |
| Head of Global Corporate Communication | no data | geen gegevens | geen gegevens | |
| Head of Sustainability | no data | geen gegevens | geen gegevens | |
| VP & Head of Neuroscience TA New Medicines | no data | geen gegevens | geen gegevens |
5.9yrs
Gemiddelde duur
59.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van UCB is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 12.2yrs | €12.43m | geen gegevens | |
| Honorary Chairman | no data | €70.00k | geen gegevens | |
| Honorary Chairman | 21.4yrs | €15.50k | geen gegevens | |
| Honorary Deputy Chairman | no data | €28.50k | geen gegevens | |
| Honorary Chairman | no data | €30.00k | geen gegevens | |
| Honorary Chairman | 5.2yrs | €87.50k | geen gegevens | |
| Honorary Chairman | no data | €49.00k | geen gegevens | |
| Independent Director | less than a year | geen gegevens | geen gegevens | |
| Independent Chair of the Board | 5.2yrs | €438.33k | geen gegevens | |
| Vice-Chair of the Board | 14.2yrs | €192.33k | geen gegevens | |
| Independent Director | 2.4yrs | €197.33k | geen gegevens | |
| Director | 12.2yrs | €157.83k | geen gegevens |
8.7yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van UCB wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.7 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/09 09:28 |
| Aandelenkoers aan het einde van de dag | 2026/06/09 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
UCB SA wordt gevolgd door 37 analisten. 16 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Charles Pitman | Barclays |
| Brian Bourdot | Barclays |
| Kerry Holford | Berenberg |